great post @KingBuzzo get some thinking… so if Amgen do nothing lose patent life and becomes a generic. If P2 CPACS gets accelerated approval. Could Race no simply pair with generic off label and patent?
what is more likely, Amgen find some other combo that improves anti-cancer perhaps increasing side effects.
Pairs with Bisantrene so anti-cancer and cardio protect exclusivity and increases MTD.
When do we hear from Amgen next? My thinking is after P1 readouts. It’s also a foot in the door of Amgen want CPACS+Dox
Ann: Bisantrene Highly Active in a Multiple Myeloma Mouse Model, page-55
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.75 |
Change
0.010(0.57%) |
Mkt cap ! $298.0M | |||
| Open | High | Low | Value | Volume |
| $1.73 | $1.83 | $1.73 | $272.0K | 152.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9998 | $1.75 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.79 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |